MSF Access Campaign

CHA

Tag: MSF Access Campaign

As Gavi plans next five-year strategy, it must do more to get vaccines to people excluded from vaccination

With routine vaccination efforts failing to reach people in fragile and emergency settings, MSF is seeing low vaccination coverage and more outbreaks of vaccine-preventable diseases, like diphtheria and measles  Geneva, 15 April 2024 – Ahead of Gavi, the Vaccine Alliance’s Board...

Read more

Time for $5: MSF demands Cepheid and Danaher lower the price of medical tests

Help us stop the profiteering on medical tests Sign the petition to demand drug manufacturers Cepheid and Danaher drop the price of GeneXpert tests for low- and middle-income countries. MSF and partners protest outside Danaher in Washington, DC, demanding price...

Read more

MSF response to signing of EFTA-India trade agreement

Geneva/Delhi, 12 March 2024: On 10 March 2024, it was announced that India and the European Free Trade Association (EFTA) signed a free trade agreement (FTA) they have been negotiating since 2006. Full text of agreement along with Annex and the Record...

Read more

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

The World Health Organization’s (WHO) 2023 Global Tuberculosis (TB) Report released today shows that the estimated global incidence of TB in 2022 remains unacceptably high, including for the more difficult to treat form of this disease, drug-resistant TB (DR-TB). With...

Read more

MSF: TB test price reduction by Cepheid and Danaher is an important step in the right direction

Cepheid and its parent company Danaher announced today that they are reducing the price of the Xpert MTB/RIF test for TB by 20 percent in high-TB-burden countries from US$9.98 to $7.97 per test.  This reduction is a significant step, considering the...

Read more

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse...

Read more

Transforming lives in Mozambique: surgical treatment for patients with neglected diseases in Mogovolas district

Nampula, July 21 , 2023 – Médecins Sans Frontières/Doctors Without Borders (MSF) is collaborating with the District Services of Health, Women and Social Action in Mogovolas and the Provincial Services in Nampula, Mozambique, to deliver surgical treatment for hydrocele, one...

Read more

Gavi must do more as WHO/UNICEF estimates show slow childhood vaccination recovery

Gavi should waive co-financing requirements for countries with fragile health systems or in humanitarian crises.Geneva, 18 July, 2023 — Today, Médecins Sans Frontières/Doctors Without Borders (MSF) again called on Gavi, the Vaccine Alliance to broaden “catch-up” vaccine coverage for unprotected...

Read more

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...

Read more

TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries

Christophe Perrin, TB advocacy pharmacist, MSF Access Campaign  "Today's announcement by the Stop TB Partnership/Global Drug Facility about a deal with pharmaceutical corporation Johnson & Johnson (J&J), for access to affordable generic versions of the lifesaving tuberculosis (TB) drug bedaquiline, offers...

Read more

MSF is disappointed with the inadequate outcome after nearly two years of discussions at the WTO

Today, more than 20 months since India and South Africa first proposed a landmark intellectual property (IP) Waiver for COVID-19 medical tools at the World Trade Organization (WTO), governments have reached a decision at the 12th WTO Ministerial Conference in...

Read more

MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multi drug-resistant TB

Geneva, 3rd May, 2022 - Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World...

Read more
Show Buttons
Share On Facebook
Share On Twitter
Share On Linkedin
Contact us
Hide Buttons